Aim Apixaban is an oral factor X a inhibitor approved for stroke prevention in atrial fibrillation
and thromboprophylaxis in patients who have undergone elective hip or knee replacement …

Aim Apixaban is an oral, direct, factor‐X a inhibitor approved for thromboprophylaxis in
patients who have undergone elective hip or knee replacement surgery and for prevention …

Aims To evaluate apixaban single dose safety, tolerability, pharmacokinetics and
pharmacodynamics and assess the effect of food on apixaban pharmacokinetics. Methods A …

Aim To assess pharmacokinetic and pharmacodynamic interactions between naproxen (a
non‐steroidal anti‐inflammatory drug) and apixaban (an oral, selective, direct factor‐X a …

Aim Apixaban is an orally active inhibitor of coagulation factor Xa and is eliminated by
multiple pathways, including renal and non‐renal elimination. Non‐renal elimination …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Abstract Background and Objectives The effects of age and sex on apixaban
pharmacokinetics and pharmacodynamics were studied. Methods This was an open-label …

An ability to readily determine an anticoagulant effect with an emerging class of direct, active
site, oral factor Xa inhibitors is viewed by the medical community as attractive and by some …

Apixaban is a potent, highly selective, reversible, oral, direct factor Xa (fXa) inhibitor in
development for thrombosis prevention and treatment. The preclinical pharmacokinetic (PK) …

Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)
phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide), a direct inhibitor …